Search

Your search keyword '"van Rood, Johannes J."' showing total 8 results
Start Over Author "van Rood, Johannes J."
8 results on '"van Rood, Johannes J."'

2. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

Author

Welters, Marij J. P., Kenter, Gemma G., de Vos van Steenwijk, Peggy J., Löwik, Margriet J. G., der Meer, Dorien M. A. Berends-van, Essahsah, Farah, Stynenbosch, Linda F. M., Vloon, Annelies P. G., Ramwadhdoebe, Tamara H., Piersma, Sytse J., van der Hulst, Jeanette M., Valentijn, A. Rob P. M., Fathers, Lorraine M., Drijfhout, Jan W., Franken, Kees L. M. C., Oostendorp, Jaap, Fleuren, Gert Jan, Melief, Cornelis J. M., van der Burg, Sjoerd H., and van Rood, Johannes J.

Published
2010

7. Identification of phosphatidylinositol 4-kinase type II [beta] as HLA class II-restricted target in graft versus leukemia reactivity

Author

Griffioen, Marieke, van der Meijden, Edith D., Slager, Elisabeth H., Honders, M. Willy, Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., von dem Borne, Peter A., van Rood, Johannes J., Willemze, Roel, and Falkenburg, J.H. Frederik

Subjects
Immunotherapy -- Research, Leukemia -- Care and treatment, Lymphocytes -- Properties, Stem cells -- Transplantation, Stem cells -- Research, Phosphotransferases -- Properties, HLA class II antigens -- Properties, Science and technology
Abstract

Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alIoSCT) and subsequent donor lymphocyte infusions (DLIs). The efficacy of DLI is mediated by donor T cells recognizing minor histocompatibility antigens (mHags) on malignant recipient cells. Because HLA class II molecules are predominantly expressed on hematopoietic cells, mHag-specific [CD4.sup.+] T cells may selectively mediate graft versus leukemia (GvL) reactivity without graft versus host disease (GvHD). In this study, we used a recombinant bacteria cDNA library for the identification of the first autosomal HLA class II (HLA-DQBl*0603)-restricted mHag LBPI4K2B-1S encoded by the broadly expressed phosphatidylinositol 4-kinase type II [beta] gene. A polyclonal [CD4.sup.+] T cell response against LB-PI4K2B-1S was demonstrated in a patient with relapsed chronic myeloid leukemia (CML) who responded to DLI after HLA-matched alIoSCT. LB-PI4K2B-1S-specific [CD4.sup.+] T cells recognized and lysed the [CD34.sup.+] CML cells of the patient and other leukemic cells as well as high HLA-DQ-expressing normal hematopoietic cells. HLA-DQ expression on normal cells of nonhematopoietic origin was moderately up-regulated by IFN-[gamma], and not sufficient for T cell recognition. We hypothesize that LB-PI4K2B-1S-specific [CD4.sup.+] T cells contributed to the antitumor response by both directly eliminating malignant cells as effector cells and stimulating [CD8.sup.+] T cell immunity as helper cells. donor lymphocyte infusions | hematological malignancies | immunotherapy | stem cell transplantation | T lymphocytes

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results